These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Developing Therapy for Transthyretin Amyloidosis. Campbell CM; Zhang K; Lenihan DJ; Witteles R Am J Med; 2022 Apr; 135 Suppl 1():S44-S48. PubMed ID: 35077703 [TBL] [Abstract][Full Text] [Related]
9. Cytodiagnosis and protein typing of amyloid from a vitreous washing: initial diagnostic workup of hereditary amyloidosis. Coppock JD; Dusenbery AC; Elghawy O; Fellenstein LA; Frierson HF; Shildkrot Y J Am Soc Cytopathol; 2020; 9(3):173-176. PubMed ID: 32113804 [TBL] [Abstract][Full Text] [Related]
10. Hereditary ATTR amyloidosis: a single-institution experience with 266 patients. Swiecicki PL; Zhen DB; Mauermann ML; Kyle RA; Zeldenrust SR; Grogan M; Dispenzieri A; Gertz MA Amyloid; 2015; 22(2):123-31. PubMed ID: 26017327 [TBL] [Abstract][Full Text] [Related]
11. TTR Gene Silencers for Hereditary ATTR Amyloidosis: More than ICER Recognized. Berk JL J Manag Care Spec Pharm; 2019 Jan; 25(1):15-16. PubMed ID: 30589634 [TBL] [Abstract][Full Text] [Related]
12. Early diagnosis and management of patients with familial ATTR amyloidosis receiving livers from asymptomatic variant TTR carriers. Munar-Qués M; Viader-Farré C; Zabay-Becerril JM; Mulet-Ferrer JM Amyloid; 2011 Sep; 18(3):172-3. PubMed ID: 21774739 [TBL] [Abstract][Full Text] [Related]
13. Successful use of palliative inotrope therapy in end-stage cardiac ATTR amyloidosis. Panhwar MS; Al-Kindi S; Oliveira GH; Ginwalla M Amyloid; 2017 Dec; 24(4):217-218. PubMed ID: 28868918 [No Abstract] [Full Text] [Related]
14. Factors associated with increased health-related quality-of-life benefits in hereditary transthyretin amyloidosis polyneuropathy patients treated with inotersen. Karam C; Brown D; Yang M; Done N; Dieye I; Bozas A; Vera Llonch M; Signorovitch J Muscle Nerve; 2022 Sep; 66(3):319-328. PubMed ID: 35766224 [TBL] [Abstract][Full Text] [Related]
15. Advances in the treatment of hereditary transthyretin amyloidosis: A review. Gertz MA; Mauermann ML; Grogan M; Coelho T Brain Behav; 2019 Sep; 9(9):e01371. PubMed ID: 31368669 [TBL] [Abstract][Full Text] [Related]
16. Inotersen (transthyretin-specific antisense oligonucleotide) for treatment of transthyretin amyloidosis. Benson MD; Dasgupta NR; Monia BP Neurodegener Dis Manag; 2019 Feb; 9(1):25-30. PubMed ID: 30561247 [TBL] [Abstract][Full Text] [Related]
17. Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial. Brannagan TH; Wang AK; Coelho T; Waddington Cruz M; Polydefkis MJ; Dyck PJ; Plante-Bordeneuve V; Berk JL; Barroso F; Merlini G; Conceição I; Hughes SG; Kwoh J; Jung SW; Guthrie S; Pollock M; Benson MD; Gertz M; Eur J Neurol; 2020 Aug; 27(8):1374-1381. PubMed ID: 32343462 [TBL] [Abstract][Full Text] [Related]
18. Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis. Brown EE; Lee YZJ; Halushka MK; Steenbergen C; Johnson NM; Almansa J; Tedford RJ; Cingolani O; Russell SD; Sharma K; Judge DP Amyloid; 2017 Jun; 24(2):92-95. PubMed ID: 28494620 [TBL] [Abstract][Full Text] [Related]
19. Inotersen for the Treatment of Hereditary Transthyretin Amyloidosis. Mahfouz M; Maruyama R; Yokota T Methods Mol Biol; 2020; 2176():87-98. PubMed ID: 32865784 [TBL] [Abstract][Full Text] [Related]
20. Origin of sporadic late-onset hereditary ATTR Val30Met amyloidosis in Japan. Ueda M; Yamashita T; Misumi Y; Masuda T; Ando Y Amyloid; 2018 Sep; 25(3):143-147. PubMed ID: 30486687 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]